The Cost of The Use of Prophylactic Anticoagulant Drugs in the Covid-19 Pandemic on the Late Period of Neurosurgery Practice

Year 2025, Volume: 11 Issue: 1, 22 - 29, 28.02.2025

Hıdır Özer , Deniz Güneş

https://doi.org/10.19127/mbsjohs.1513695

Abstract

Objective: After being reported for in Wuhan, China, -stranded RNA coronavirus, COVID-19 leading to the deaths of thousands of people. Patients hospitalized in intensive care units (ICUs) who develop acute respiratory distress syndrome (ARDS) due to COVID-19 typically exhibit respiratory and digestive system symptoms. However, coagulopathy, which indicates a poor prognosis, may also develop in some patients receiving care in ICUs.This article aims to examine the economic consequences of prophylactic anticoagulant and antiplatelet drug use on neurosurgery practice during the late period of the COVID-19 pandemic.
Methods: This study retrospectively examined patients hospitalized for surgical treatment in the Neurosurgery Clinic of Ordu University Training and Research Hospital between January 1 and December 31, 2022. A total of 38 out of 320 patients were diagnosed with COVID-19, and cost analysis was specifically performed on these patients. Data were obtained from the hospital's data system.
Results: An increase in costs was observed in both spine surgery and cranial surgery due to drug use. The Kruskal-Wallis Test showed a significant difference in bed costs between patients who received anticoagulant or antiplatelet-anticoaggregant medication and those who did not (P=.000).
Conclusion: The use of prophylactic anticoagulant and antiplatelet drugs significantly extended the length of hospital stay for patients in both pre-operative and post-operative periods, resulting in increased costs for the social security institution.

Keywords

COVID-19, anticoagulant drugs, antiplatelet drugs, treatment cost, spinal surgery, cranial surgery, healthcare economics

References

• Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y. et. al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, 2020;395(10223), 507–513.
• Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, et. al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci. 2020; 63(3): 457–460.
• Glass, W. G., Subbarao, K., Murphy, B., & Murphy, P. M. (2004). Mechanisms of host defense following severe acute respiratory syndrome-Coronavirus (SARS-CoV) pulmonary infection of mice. The Journal of Immunology, 2004;173(6):4030–4039.
• Emanuel, E. J., Persad, G., Upshur, R., Thome, B., Parker, M., Glickman, A., Zhang, C., et. al Fair allocation of scarce medical resources in the time of covid-19. The New England Journal of Medicine, 2020;382(21): 2049–2055. https://doi.org/10.1056/NEJMsb2005114
• Arachchillage DRJ, Laffan M. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of Thrombosis and Haemostasis: JTH, 2020;18(5):1233–1234.
• Hays, J. N. (2005). Epidemics and pandemics: Their impacts on human history. California: ABC-CLIO.
• Yamin M. Counting the cost of COVID-19. Int J Inf Technol. 2020;12(2): 311–317.
• Gómez-Mesa JE, Galindo-Coral S, Montes MC, Muñoz Martin AJ. Thrombosis and Coagulopathy in COVID-19. Curr Probl Cardiol. 2021;46(3):100742. doi: 10.1016/j.cpcardiol.2020.100742. Epub 2020 Nov 2. PMID: 33243440; PMCID: PMC7605852.
• Al-Ani, F., Chehade, S., & Lazo-Langner, A. Thrombosis risk associated with COVID-19 infection. A scoping review. Thrombosis Research. 2020;192:152–160.
• Matli K, Farah R, Maalouf M, Chamoun N, Costanian C, Ghanem G. Role of combining anticoagulant and antiplatelet agents in COVID-19 treatment: a rapid review. Open Heart. 2021;8(1):e001628.
• Dobesh PP, Trujillo TC. Coagulopathy, venous thromboembolism, and anticoagulation in patients with COVID-19. Pharmacotherapy. 2020;40(11):1130–1151.
• Carrera-Hueso FJ, Álvarez-Arroyo L, Poquet-Jornet JE, et al. Hospitalization budget impact during the COVID-19 pandemic in Spain. Health Economics Review. 2021;11(1): 43.
• Di Fusco M, Shea KM, Lin J Nguyen JL, Angulo FJ, Benigno M. et al. Health outcomes and economic burden of hospitalized COVID-19 patients in the United States. Journal of Medical Economics. 2021; 24(1): 308–317.
• Ohsfeldt RL, Choong CK-C, Mc Collam PL, Abedtash H, Kelton KA, Burge R. Inpatient hospital costs for COVID-19 patients in the United States. Adv Ther. 2021;38(11):5557–5595.
• Aghajani MH, Sistanizad M, Toloui A, Neishaboori AM, Pourhoseingholi A, Maher A, Yousefifard. COVID-19 related hospitalization costs; assessment of influencing factors. Frontiers in Emergency Medicine. 2022; 6(1): e3–e3.
• Satiani B, Davis CA. The financial and employment effects of coronavirus disease 2019 on physicians in the United States. J Vasc Surg. 2020;72(6):1856-1863.
• China Economic Quarterly. 2020. Available from: https://www.pwccn.com/en/research-and-insights/china-economic-quarterly-q1-2020.pdf.
• Leonardo J. Impact of COVID-19 on Neurosurgery in Brazil’s Health System: The Reality of a Developing Country Affected by the Pandemic. World Neurosurgery. 2021; 155: e142–e149.
• Sivakanthan S, Pan J, Kim L, Ellenbogen R, Saigal R. Economic impact of COVID-19 on a high-volume academic neurosurgical practice. World Neurosurg. 2020;143:e561–e566.
• Jean WC, Ironside NT, Sack KD, Felbaum DR, Syed HR. The impact of COVID-19 on neurosurgeons and the strategy for triaging non-emergent operations: a global neurosurgery study. Acta Neurochirurgica. 2020;162(6):1229–1240.
• Ozoner B, Gungor A, Hasanov T, Toktas ZO, Kilic T. Neurosurgical practice during Coronavirus disease 2019 (COVID-19) pandemic. World Neurosurg. 2020;140:198–207.
• Barnes GD, Burnett A, Allen A, Blumenstein M, Clark NP, Cuker A, et al. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. Journal of Thrombosis and Thrombolysis. 2020; 50(1): 72–81.